Cargando…

Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease

Low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp(a)) are established causal risk factors for cardiovascular disease (CVD). Efficacy, safety, and tolerability of lipoprotein apheresis (LA) were investigated in 118 patients with CVD covering a period with 36,745 LA treatments in a re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heigl, Franz, Hettich, Reinhard, Lotz, Norbert, Reeg, Harduin, Pflederer, Tobias, Osterkorn, Dirk, Osterkorn, Klaus, Klingel, Reinhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361749/ https://www.ncbi.nlm.nih.gov/pubmed/25672934 http://dx.doi.org/10.1007/s11789-015-0071-3

Ejemplares similares

Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy – successful treatment with lipoprotein apheresis
por: Heigl, Franz, et al.
Publicado: (2017)

Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines
por: Klingel, Reinhard, et al.
Publicado: (2017)

Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2021)

Familial Hypercholesterolemia and Lipoprotein Apheresis
por: Makino, Hisashi, et al.
Publicado: (2019)

Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels
por: Schettler, Volker J. J., et al.
Publicado: (2015)

Characteristics of carotid atherosclerotic plaques of chronic lipid apheresis patients as assessed by In Vivo High-Resolution CMR - a comparative analysis
por: Grimm, Jochen M, et al.
Publicado: (2012)

Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia
por: Connolly, Katherine D., et al.
Publicado: (2014)

Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe study
por: Klingel, Reinhard, et al.
Publicado: (2015)

LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective
por: Kayikcioglu, Meral
Publicado: (2021)

First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection
por: Torzewski, Jan, et al.
Publicado: (2020)

Unbiased estimation of the breeding value of bulls
por: Osterkorn, K
Publicado: (1976)

Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection
por: Julius, Ulrich
Publicado: (2016)

Pregnancy in a Woman with Homozygous Familial Hypercholesterolemia Not on Low-Density Lipoprotein Apheresis
por: Fahed, Akl C., et al.
Publicado: (2012)

Systematic Review of Low‐Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia
por: Wang, Anthony, et al.
Publicado: (2016)

Improvement of oxidative stress status by lipoprotein apheresis in Chinese patients with familial hypercholesterolemia
por: Wen, Jun, et al.
Publicado: (2019)

Immunoadsorption as maintenance therapy for refractory neuromyelitis optica spectrum disorder
por: Heigl, Franz, et al.
Publicado: (2023)

Current Role of Lipoprotein Apheresis
por: Thompson, Gilbert, et al.
Publicado: (2019)

Case of familial hyperlipoproteinemia type III hypertriglyceridemia induced acute pancreatitis: Role for outpatient apheresis maintenance therapy
por: Saleh, Mohannad Abou, et al.
Publicado: (2017)

Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis center
por: Mickiewicz, Agnieszka, et al.
Publicado: (2020)

The German Lipoprotein Apheresis Registry (GLAR) – almost 5 years on
por: Schettler, V. J. J., et al.
Publicado: (2017)

An update on lipid apheresis for familial hypercholesterolemia
por: Taylan, Christina, et al.
Publicado: (2022)

Myeloperoxidase modulation by LDL apheresis in Familial Hypercholesterolemia
por: Puntoni, Mariarita, et al.
Publicado: (2011)

Usefulness of Lipid Apheresis in the Treatment of Familial Hypercholesterolemia
por: Lui, Matthew, et al.
Publicado: (2014)

Successful Direct Adsorption of Lipoproteins (DALI) Apheresis During Pregnancy in an Omani Woman with Homozygous Familial Hypercholesterolemia
por: Al-Dughaishi, Tamima, et al.
Publicado: (2015)

A selection programme for trotting horses
por: Kräusslich, H, et al.
Publicado: (1976)

Fibrinogen/LDL apheresis is a promising rescue therapy for sudden sensorineural hearing loss
por: Canis, Martin, et al.
Publicado: (2012)

Therapeutic management of hyperlipoproteinemia (a)
por: Kosmas, Constantine E, et al.
Publicado: (2019)

Beziehungen zwischen den eigenleistungsergebnissen von prüfbullen und den abkalbeergebnissen aus dem testeinsatz
por: Averdunk, G, et al.
Publicado: (1978)

Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients
por: Víšek, J., et al.
Publicado: (2021)

Low-density lipoprotein cholesterol goal attainment in patients with clinical evidence of familial hypercholesterolemia and elevated Lp(a)
por: Schwarz, Andrea, et al.
Publicado: (2022)

Genetic components affecting the interval between consecutive inseminations
por: Anan, R Bar, et al.
Publicado: (1978)

Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab
por: Tanaka, Akihito, et al.
Publicado: (2017)

The effect of DALI lipid apheresis in the prognosis of homozygous familial hypercholesterolemia: Seven patients' experience at a DALI apheresis center
por: Bulut, Muhammet, et al.
Publicado: (2020)

Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons
por: Torzewski, Jan, et al.
Publicado: (2022)

HELP LDL Apheresis Reduces Plasma Pentraxin 3 in Familial Hypercholesterolemia
por: Zanetti, Michela, et al.
Publicado: (2014)

Impact of selective LDL apheresis on serum chemerin levels in patients with hypercholesterolemia
por: Varga, Viktória E., et al.
Publicado: (2016)

Vascular access for lipid apheresis: a challenge in young children with homozygous familial hypercholesterolemia
por: Lischka, Julia, et al.
Publicado: (2022)

Therapeutic apheresis in autoimmune diseases
por: Bambauer, Rolf, et al.
Publicado: (2013)

Serum enzymes and metabolites related with high production and longevity
por: Graf, F, et al.
Publicado: (1976)

Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
por: Greco, Maria Francesca, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kmmv9b70cpolb4vcvcdbdi2bqk